Page 484 - Read Online

Gajjar et al. ERCC1 in colorectal cancer

Figure 2: Representative staining of ERCC1 (×40). (A) Colon cancer; (B) colon cancer; (C) rectal cancer; (D) negative control. ERCC1:
excision repair cross complementation group 1

Univariate survival analysis according to chemotherapy and have the potential to be used as
ERCC1 codon 118 C/T polymorphism and candidate biomarkers for CRC. Therefore, the present
ERCC1 protein expression study explored the role of ERCC1 C118T SNP as well
When patients were stratified according to ERCC1- as ERCC1 immunoreactivity in CRC patients.
118 polymorphism, it was observed that both patients
(100%) who had developed relapse had the C/T A predominance of the C/T genotype (52%) was
genotype, whereas amongst the 5 patients who died, observed as compared to C/C (38%) and T/T (10%)
2 (40%) each had the C/C and C/T genotypes, and genotypes. In accordance with the current study,
one (20%) had T/T. Further, when patients were one CRC study reported a higher incidence of the
stratified according to ERCC1 protein expression, of C/T genotype, with 44% as compared to C/C (24%)
the 2 who developed recurrences, one (50%) was and T/T (32%). However, another reported that
[12]
ERCC1-positive and another (50%) was ERCC1- the frequencies of C/C, C/T, and T/T genotypes
negative. Among the patients who had died, 4 (75%)
were ERCC1-positive and one (25%) was ERCC1
negative. However, the data were statistically non-
significant.

DISCUSSION

Oxaliplatin, a platinum-based chemotherapeutic drug,
induces DNA damage by forming DNA adducts. DNA
repair proteins involved in the NER pathway, such
as ERCC1, play a key role in repair of this damage,
thus leading to resistance to platinum-based therapy.
Several clinical studies have demonstrated that
both ERCC1 polymorphism and protein expression Figure 3: Significant correlation of ERCC1 protein expression
with tumor site; P = 0.046 between the colon and rectum groups.
are associated with resistance to platinum-based ERCC1: excision repair cross complementation group 1
474 Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ December 29, 2016